Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H13F3OSi |
| Molecular Weight | 246.301 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[Si](C)(C)C1=CC(=CC=C1)C(=O)C(F)(F)F
InChI
InChIKey=GAPOASFZXBWUGS-UHFFFAOYSA-N
InChI=1S/C11H13F3OSi/c1-16(2,3)9-6-4-5-8(7-9)10(15)11(12,13)14/h4-7H,1-3H3
| Molecular Formula | C11H13F3OSi |
| Molecular Weight | 246.301 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7781701
Curator's Comment: Zifrosilone is CNS active in animal model. No human data available.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7628183
Pharmacokinetics, pharmacodynamics, and tolerance of zifrosilone were studied in a double-blind, sequential, single-escalating-dose, randomized panel design. Each panel consisted of six subjects, with four subjects receiving zifrosilone (10, 30, 60, 90, 120, 150, 200, 250, and 300 mg orally) and two subjects receiving matching placebo.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:42:49 GMT 2025
by
admin
on
Wed Apr 02 08:42:49 GMT 2025
|
| Record UNII |
6275788O83
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C47792
Created by
admin on Wed Apr 02 08:42:49 GMT 2025 , Edited by admin on Wed Apr 02 08:42:49 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
7210
Created by
admin on Wed Apr 02 08:42:49 GMT 2025 , Edited by admin on Wed Apr 02 08:42:49 GMT 2025
|
PRIMARY | |||
|
C082826
Created by
admin on Wed Apr 02 08:42:49 GMT 2025 , Edited by admin on Wed Apr 02 08:42:49 GMT 2025
|
PRIMARY | |||
|
C82222
Created by
admin on Wed Apr 02 08:42:49 GMT 2025 , Edited by admin on Wed Apr 02 08:42:49 GMT 2025
|
PRIMARY | |||
|
132236-18-1
Created by
admin on Wed Apr 02 08:42:49 GMT 2025 , Edited by admin on Wed Apr 02 08:42:49 GMT 2025
|
PRIMARY | |||
|
SUB00154MIG
Created by
admin on Wed Apr 02 08:42:49 GMT 2025 , Edited by admin on Wed Apr 02 08:42:49 GMT 2025
|
PRIMARY | |||
|
100000079416
Created by
admin on Wed Apr 02 08:42:49 GMT 2025 , Edited by admin on Wed Apr 02 08:42:49 GMT 2025
|
PRIMARY | |||
|
6275788O83
Created by
admin on Wed Apr 02 08:42:49 GMT 2025 , Edited by admin on Wed Apr 02 08:42:49 GMT 2025
|
PRIMARY | |||
|
EE-17
Created by
admin on Wed Apr 02 08:42:49 GMT 2025 , Edited by admin on Wed Apr 02 08:42:49 GMT 2025
|
PRIMARY | |||
|
DTXSID80157445
Created by
admin on Wed Apr 02 08:42:49 GMT 2025 , Edited by admin on Wed Apr 02 08:42:49 GMT 2025
|
PRIMARY | |||
|
60811
Created by
admin on Wed Apr 02 08:42:49 GMT 2025 , Edited by admin on Wed Apr 02 08:42:49 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|